Cancer Management and Research (May 2020)
Double Agent: SPDEF Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer
Abstract
Ting Ye,* Jia Feng,* Xue Wan, Dan Xie, Jinbo Liu Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan 646000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jinbo LiuDepartment of Laboratory Medical, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou 646000, Sichuan, People’s Republic of ChinaTel +86830 3165730Email [email protected]: The dichotomy of cancer-regulatory genes into “oncogenes (OCGs)” and “tumor-suppressor genes (TSGs)” has greatly helped us in learning molecular details of tumor biology. SPDEF, known as the prostate-derived ETS factor, is reported to play a pivotal role in normal cell development and survival, which has also been endowed with dual characteristics in cancers. Breast cancer (BC) is a highly heterogeneous disease which becomes the leading reason for cancer-related fatality among women worldwide. The involvement of SPDEF in many aspects of BC has been postulated, whereas the mechanism governing the regulation of the pro- and anti-oncogenic activities of SPDEF in BC state remains poorly defined. In this review, we summarized SPDEF as the double agent involving in expression profiles, the regulatory mechanism in BC progression, as well as the role in diagnosis, treatment and prognosis of BC. The understanding of SPDEF duality has contributed to gain insight into the tumor biology and also add a new dimension to the new therapy targets for BC.Keywords: SPDEF, double agent, oncogenes, tumor-suppressor genes, transcription factor, breast cancer
